Featured Articles

Atrix and Fujisawa submit NDA for t...

Atrix Laboratories and Fujisawa Healthcare have submitted a new drug application to the FDA for Aczone Gel (5% dapsone...

The FDA approves new leukemia drug;...

The FDA has granted accelerated approval for Sprycel (dasatinib), a new oral treatment for people with chronic myeloid...

NEWS BRIEFS. - Free Online Library<...

Protein linked to HIV entry. A protein molecule found in dendritic cells, which commonly line the rectum, cervix and...

Clonazepam | Gale Encyclopedia of M...

Clonazepam

Chronic headaches: sometimes due to...

The most effective drugs for the relief of headaches can also cause headaches when overused. This paradox, known as an...

FIND A DRUG

Pharmacy Locator

ZIP Distance

Use this tool to find
pharmacies in your area

Drug Information Related to Abelcet

Back

01. Approved Drugs for HIV/AIDS or AIDS-related Conditions. - Free Online ...

July 6, 1999 * Abacavir abacavir /abac·a·vir/ (ah-bak´ah-vir) a nonnucleoside reverse transcriptase inhibitor used as the sulfate salt as an antiretroviral in the treatment of human immunodeficiency virus infection. (Ziagen), Glaxo Wellcome Approved De...

02. Enzon Pharmaceuticals Secures Supply of Oncaspar. - Free Online Librar...

Important Outcome for Children with ALL BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced it entered into an agreement with Ovation Pharmaceuticals, Inc. for the supply of the active ingredient used in the production of Enzon's Oncaspar...

03. SEQUUS Pharmaceuticals, Inc. announces first quarter results. - Free ....

MENLO PARK, Calif.--(BUSINESS WIRE)--April 29, 1997--SEQUUS Pharmaceuticals, Inc. (Nasdaq: SEQU) today announced financial results for the first quarter ended March 31, 1997. The Company reported an 85% increase in total revenues for the first quarter of 1997 as...

04. USP 797: meeting customer challenges. - Free Online Library

New regulations to increase health care worker accountability for compounding sterile preparations and safe handling of pharmaceuticals are affecting how hospitals and clinics select and administer parenteral medications. These regulations also are affecting the ...

05. Enzon Provides Clinical Updates on Three Oncology Candidates at Annual...

Business Editors/Health/Medical Writers 40th Annual Meeting of the American Society of Clinical Oncology BRIDGEWATER, N.J.--(BUSINESS WIRE)--June 7, 2004 Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) -- Onco TCS Demonstrates Potential in the First-Line Setting for N...

06. AmBisome Demonstrates Superior Safety Profile Compared to Abelcet in ....

( BW)(CA-FUJISAWA Fujisawa (fjē`säwä), city (1990 pop. 350,330), Kanagawa prefecture, central Honshu, Japan, on Sagami Bay. It is an industrial and residential suburb of Tokyo, known for the production of automobiles, electric appliances, and iron...

07. Study Results Published in Journal of Clinical Infectious Diseases ......

Business Editors/Health & Medical Writers DEERFIELD, Ill. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 17, 2000 First Head-to-Head, Blinded Safety Comparison of Lipid-Based Amphotericin B amphotericin B /am·pho·ter·i·cin B/ (-ter´i-sin) an antibi...

08. Sequus Pharmaceuticals' AMPHOTEC product significantly more effective ...

MENLO PARK, Calif.--(BUSINESS WIRE)--April 1, 1997--SEQUUS Pharmaceuticals, Inc. (Nasdaq:SEQU) today announced results of a preclinical study comparing AMPHOTEC(TM) to amphotericin B amphotericin B /am·pho·ter·i·cin B/ (-ter´i-sin) an antibiotic derived ...

09. Enzon to Launch CLEAR II Registry; New Initiative Reinforces Commitmen...

Business Editors/Health/Medical Writers/High-Tech Writers BRIDGEWATER, N.J--(BUSINESS WIRE)--March 24, 2004 Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today a major new initiative to build upon the value of its CLEAR(R) (Collaborative Exchange of Antifung...

10. Enzon to Present Preclinical Data On HIF-1alpha antagonist at AACR ......

Company will host informative reception ...

11. Enzon Reports Significant Progress on the Reduction of Its Debt ......

Only $12.5 million in 2008 debt remaining ...

12. Jack Geltosky, Ph.D. Joins Enzon's Board of Directors | Business Wire ...

BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Dr. Jack Geltosky has been appointed to the Company's Board of Directors. ...

13. Enzon Eliminates Its Remaining 2008 Debt | Business Wire | Find ......

BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today it has successfully eliminated all of its remaining 2008 debt. ...

14. Enzon Completes Acquisition of Abelcet North American Business From .....

Business/Health Editors ...

15. Drug research heavy in region | Mercer Business | Find Articles at BNE...

Cancer is a most formidable enemy, an adversary whose very name is fearsome. Many of the strategies and weapons to be used in the war against its relentless onslaughts are being developed within Mercer County at medical research and development facilities. ...

16. Lipid-based or conventional? | Nursing | Find Articles at BNET.com...

Serious medication errors, some fatal, have occurred because of confusion between certain lipid-based (liposomal) drugs and their conventional counterparts. The drugs involved include: ...

17. Enzon/Inex Sign Commercialization Pact For Oncology Drug Onco Tcs ......

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) and Inex Pharmaceuticals Corporation (TSX: IEX) have formed a strategic partnership to develop and commercialize INEX's proprietary oncology product Onco TCS. ...

18. Amphotericin B reaction | Nursing | Find Articles at BNET.com

A 33-YEAR-OLD MAN was being treated for meningitis with amphotericin B through an intraventricular reservoir. Despite pretreatment medications, he experienced adverse reactions from the infusion and his infection progressed to the lumbosacral vertebral area. The intrave...